Login / Signup

Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature.

Magdalena WlazłoJaroslaw Kierkus
Published in: Journal of clinical medicine (2022)
the use of dual biological therapy is a new therapeutic option. In pediatric IBD, combining the different mechanisms of action of the two biological drugs seems to be safe and effective. Anti-TNF drugs with vedolizumab or ustekinumab may be a particularly beneficial combination. Nevertheless, the clarification and justification of potential advantages of combined biological therapies in further studies, such as randomized control trials, are needed.
Keyphrases
  • rheumatoid arthritis
  • ulcerative colitis
  • double blind
  • open label
  • randomized controlled trial
  • clinical trial
  • phase iii
  • young adults
  • drug induced
  • human health
  • climate change
  • childhood cancer